-
MeiraGTx Advances Late-Stage AAV Gene Therapy Programs Across Ophthalmology and Beyond
Mar 26 2026 -
Complement Therapeutics Dosed First Patient in Phase 1/2 Trial of AAV2 Gene Therapy CTx001 for Geographic Atrophy
Mar 25 2026 -
VeonGen’s Dual-AAV Gene Therapy VG801 Shows Encouraging Early Clinical Results for Stargardt Disease
Mar 25 2026 -
Beam Therapeutics Reports Positive Phase 1/2 Data for BEAM-302 Base Editing Therapy in Alpha-1 Antitrypsin Deficiency
Mar 25 2026 -
Neurogene Advances Gene Therapy NGN-401 Registrational Trial for Rett Syndrome
Mar 24 2026 -
AAV Gene Therapy BBM-H901 Approved in Macao for Hemophilia B
Mar 24 2026 -
Ocugen Reports Positive Phase 2 Data for AAV5 Gene Therapy OCU410 in Geographic Atrophy
Mar 24 2026 -
Genflow Biosciences Secures New Funding to Advance Gene Therapy Programs for Age-Related Diseases
Mar 24 2026 -
Abu Dhabi Launches First Clinical Trial for AAV Gene Therapy Targeting MerTK-Related Retinitis Pigmentosa
Mar 23 2026